Studies documenting that cytokines are potent rate-limiting signals and that some anticytokine therapies have had promising clinical success open new perspectives on the therapeutic capacity of targeting cytokines/cytokine receptors in neurological disorders. This evidence concerns the gene IL18R1 and nervous system disorder.